Global Lyme Diagnostics Announces the Addition of Tick-Borne Coinfection Testing to Groundbreaking GLD Lyme Screen

Monday, June 4, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Global Lyme Diagnostics (GLD) - launched it's ground breaking Lyme diagnostic in 2017 and is now excited to announce the launch of their tick-borne coinfections diagnostic tests.

RTP, N.C., June 4, 2018 /PRNewswire-PRWeb/ -- Global Lyme Diagnostics (GLD) – launched it's ground breaking Lyme diagnostic in 2017 and is now excited to announce the launch of

their tick-borne coinfections diagnostic tests. This additional coinfection panel gives physicians and patients the ability to test for the most common tick-borne diseases in addition to Lyme disease, including Anaplasma, Babesia Microti, Babesia Duncani, Bartonella Henselae, Bartonella Quintana, and Rickettsia including Spotted Fever Group.

Coinfections can be a significant complication in the effective treatment of Lyme disease. Ticks may carry more than one disease, making it possible for people to get more than one type of infection from a single tick bite. As recently reported on multiple news networks and by the Center for Disease Control, infections caused by ticks is spreading rapidly.

Lyme is also known as "the Great Imitator" and mimics many conditions, including flu. It is important to have a proper screening tool to diagnose Lyme and it's coinfections. Global Lyme Diagnostics is well known for the GLD Lyme-specific screen, which is designed to screen for antibodies to multiple variants and species of Lyme disease causing bacteria in one affordable test. The test's ability to screen for these multiple antibodies is what allows for fewer false negatives, and being able to do it in one test makes it more affordable.

GLD coinfection testing is the one of the most affordable, with the quickest turnaround time from test to results, and allows physicians to custom-pick the coinfections they want to test for – not forcing them to run a battery of tests on a coinfection they have already deemed unnecessary through their own analysis. This in turn allows for them to save their patients' money.

"Our mission at Global Lyme Diagnostics has been to reduce false negatives plaguing the Lyme testing assays with a test that is not only reliable, but is also affordable to a wider population," says the CEO of GLD, Mickey Ramchandani. "We are now expanding our test menu to also include multiple different co-infections that result from tick bites."

For more information, please visit our

About the GLD Lyme-Specific Screen:

The GLD test uses novel chimeritope (chimeric proteins) technology. Our chimeritope was sequenced by Dr. Marconi to use as vaccinogens or as diagnostic antigens. Each chimeritope is derived from multiple diverse outer surface C protein (OsPC) variants, strains and species of borrelia. It is this diversity of targets that allows for reduced false negatives in the GLD Test and what sets us apart from current tests.

About Global Lyme Diagnostics:

After years of research, Global Lyme Diagnostics has launched the GLD test, specific to Lyme Disease, which can be requested by clinicians at Note: The GLD Test is not yet available for PA or NY residents. More information about GLD, including the science behind the test and the GLD team is available at the website at


SOURCE Global Lyme Diagnostics

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store